A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2567-2572

  Dongiovanni, Vincenzo ^a   Addeo, Alfredo ^a   Berruti, Alfredo ^b   Buffoni, Lucio ^a   Dongiovanni, Diego ^a   Polimeni, Maria Antonia ^a   Fissore, Camilla ^a   Barone, Carla ^a   Bertetto, Oscar ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Gemcitabine; Non small cell lung cancer; Second line chemotherapy; Weekly paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; VINBLASTINE;

EID: 4444252246     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parkin DH, Pisani P, Ferlay J et al: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999.
2. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15: 2996-3018, 1997.
3. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995.
4. Cullen MH, Billingham LJ, Woodroffe CM et al: Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188-3194, 1999.
5. Sheperd F, Dancey J, Ramlau R et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-3103, 2000.
6. Fossella FV, DeVore R, Kerr RN et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy regimens. J Clin Oncol 18(12): 2354-62, 2000.
7. Socinski MA: Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 4: 408-416, 1999.
8. Georgoulias VA: Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer 38(Suppl. 3): 61-66, 2002.
9. Rose WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst Monogr 15: 47-53, 1993.
10. Chang AYC: Taxol in the treatment of non-small cell lung cancer. In: Paclitaxel in Cancer Treatment (McGuire WP, Rowinky E, eds). New York, Marcel Dekker. 1995, pp 273-279.
11. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24(Suppl. 10): 10.3-10.10, 1997.
12. Milross CG, Mason KA, Hunter NR et al: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314, 1996.
13. Belani CP: Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin Oncol 28(4Suppl 14): 14-6, 2001.
14. Esteban E, Gonzalez de Sande L, Fernandez Y et al: Prospective randomized phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 14: 1640-1647, 2003.
15. Anderson H, Hopwood P, Stephens RJ et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. Br J Cancer 83: 447-453, 2000.
16. Rosvold E, Langer CJ, Schilder R et al: Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P). Proc Am Soc Clin Oncol 17: A1797, 1998.
17. Kosmidis P, Mylonakis N, Nicolaides C et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 20: 3578-3585, 2002.
18. Van Meerbeck JP, Smith EF, Lianes P et al: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20: A1228, 2001.
19. Livingston RB: Current management of unresectable non-small-cell lung cancer. Oncology 11(Suppl. 3): 11-15, 1997.
20. Iaffaioli RV, Tortoriello A, Gravina A, Facchini G et al: Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer. Lung Cancer 30: 203-210, 2000.
21. Fleming DR, Glisson SD, Bhupalam L, Michelson GD, Goldsmith GH, LaRocca R et al: Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. Am J Clin Oncol 23(4): 349-352, 2000.
22. Hirsh V, Whittom R, Ofiara L et al: Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 97(9): 2242-2247, 2003.
23. Miller AB, Hoogstraten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-14, 1981.
24. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
25. Huisman C, Smit EF, Giaccone G et al: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18(21): 3722-3730, 2000.
26. Androulakis N, Kouroussis C, Kakolyris S et al: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 9(10): 1127-1130, 1998.
27. Einhorn L, Raghavan D, Kindler H et al: A phase I trial of gemcitabine and paclitaxel combination therapy in patients with refractory solid tumors. Proc Am Soc Clin Oncol 17: A796, 1998.
28. Bhatia S, Hanna N, Ansari R et al: A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 38(1): 73-77, 2002.
29. Seidman AD, Hudis CA, Albanel J et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. Review. J Clin Oncol 16: 3353-3361, 1998.